Brius Technologies v. Swift Health Systems & USC: Orthodontic Software Patent Dispute Dismissed
Brius Technologies brought a declaratory judgment action in the Central District of California against Swift Health Systems and the University of Southern California over US11129696B2, a patent covering orthodontic treatment planning software. After 472 days of litigation, all claims and counterclaims were voluntarily dismissed without prejudice, with each side bearing its own costs.
A declaratory judgment clash over orthodontic AI planning software
On 27 September 2022, Brius Technologies, Inc. filed suit in the United States District Court for the Central District of California (Case No. 8:22-cv-01770) against Swift Health Systems, Inc. and the University of Southern California, seeking a declaratory judgment in connection with US11129696B2. The patent relates to BRIUS Planner Software, a computer-aided orthodontic treatment planning tool cleared by the FDA under a Special 510(K) pathway. The involvement of USC as a co-defendant alongside a commercial entity suggests the patent may have university origins or licensing ties to USC’s dental or biomedical engineering programs.
The case closed on 12 January 2024 via a stipulated dismissal filed under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Critically, all claims — Brius’s original claim, any counterclaim filed by Brius, and the defendants’ counterclaim — were dismissed without prejudice. The court ordered each side to bear its own costs and fees. A without-prejudice dismissal means no party is legally barred from refiling the same claims; the patent’s validity and any infringement questions remain formally unadjudicated.
The 472-day duration before a mutual walk-away is consistent with a case that progressed through early motion practice or discovery before the parties negotiated an exit. The simultaneous dismissal of both plaintiff claims and defendant counterclaims — coupled with a cost-neutrality order — typically signals a negotiated resolution rather than a unilateral capitulation, though the public record is silent on whether any licensing arrangement, covenant not to sue, or other commercial agreement was reached.
Filing to Voluntary dismissal in 472 days
472 days — longer than the median voluntary dismissal in C.D. Cal. patent cases, suggesting substantive engagement before resolution.
Voluntarily dismissed: what the without-prejudice exit means for both parties
Rule 41(a)(1)(A)(ii): stipulated dismissal explained
A Rule 41(a)(1)(A)(ii) dismissal is a court-approved stipulation signed by all parties. It is procedurally distinct from a unilateral withdrawal — it requires mutual consent, making it a negotiated exit. Because it was entered without prejudice, no claim has been decided on the merits, and no issue-preclusion or claim-preclusion attaches. Either party could, in principle, refile substantially similar claims subject to applicable statutes of limitations.
Mutual, no merits rulingWithout prejudice — but the record is silent on underlying terms
The order expressly states dismissal ‘without prejudice,’ meaning neither party is legally foreclosed from future litigation on the same patent. However, voluntary dismissals under Rule 41(a)(1)(A)(ii) are frequently accompanied by private settlement agreements, licensing deals, or covenants not to sue that are not filed with the court. Whether such an agreement exists here is unknown from the public record — practitioners should not read the dismissal as either a concession of invalidity or an admission of infringement.
Future claims not barredBrius exits without a court ruling — patent remains intact
Brius Technologies retains US11129696B2 in its portfolio; no court has declared it invalid, unenforceable, or not infringed. The without-prejudice nature of the dismissal preserves Brius’s option to assert the patent again, whether against Swift Health Systems, USC, or new entrants. The declaratory judgment vehicle suggests Brius may have been on the receiving end of licensing pressure before filing, though this is an inference from the procedural posture rather than a stated fact.
Patent survives, options preservedSwift Health & USC avoid an adverse ruling — counterclaims also dropped
Both Swift Health Systems and USC agreed to dismiss their own counterclaims without prejudice. If those counterclaims included invalidity or non-infringement assertions, their withdrawal leaves those defenses legally available but unexercised. The cost-neutrality order is consistent with a balanced settlement, suggesting neither side secured a clear litigation advantage. Companies operating in the orthodontic planning software space should note that the underlying IP dispute has not been resolved on the merits.
Counterclaims withdrawn, dispute unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Brius Technologies, Inc. | Company | Orthodontic technology company — holder of US11129696B2 covering BRIUS Planner SoftwareSearch in Eureka ↗ |
| Defendant | Swift Health Systems, Inc. | Company | Swift Health Systems, Inc. (orthodontic device company) and University of Southern CaliforniaSearch in Eureka ↗ |
| Co-Defendant | University of Southern California | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Hari Santhanam | Attorney | Counsel for Brius Technologies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lara J. Dueppen | Attorney | Counsel for Brius Technologies, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nicole S. Dunham | Attorney | Counsel for Brius Technologies, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Brius Technologies, Inc.Search in Eureka ↗ |
| Defendant counsel | Ali Razai | Attorney | Counsel for Swift Health Systems, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin Bruce Anger | Attorney | Counsel for Swift Health Systems, Inc.Search in Eureka ↗ |
| Defendant counsel | Nicholas Andrew Belair | Attorney | Counsel for Swift Health Systems, Inc.Search in Eureka ↗ |
| Defendant law firm | Knobbe Martens Olson & Bear, LLP | Law Firm | Representing Swift Health Systems, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order mirrors the exact language of the parties’ stipulation under Rule 41(a)(1)(A)(ii), confirming that no judicial determination was made on the merits of the declaratory judgment claim, any counterclaims, or the validity of US11129696B2. The symmetric without-prejudice language covering both plaintiff and defendant claims is a deliberate drafting choice that places all parties on equal legal footing post-dismissal. The cost-neutrality provision removes any implied concession of weakness by either side.
US11129696B2 — Orthodontic treatment planning software and simulation
US11129696B2 (application number US16/292126) covers technology underlying BRIUS Planner Software, a computer-aided orthodontic treatment planning tool that received FDA clearance via the Special 510(K) pathway. The patent likely claims methods or systems for digitally simulating tooth movement, generating treatment plans, or optimising orthodontic appliance configurations — technical capabilities that are central to modern clear-aligner and customised-bracket workflows in dental practice.
This patent sits at the intersection of dental device technology and clinical software, a space experiencing rapid IP activity as digital orthodontics displaces traditional impression-based workflows. A patent covering FDA-cleared treatment planning software carries particular strategic weight: competitors whose products share functional or algorithmic overlap face both patent infringement risk and potential regulatory predicate challenges. The absence of a validity ruling following this case means the patent’s claims have not been tested before the PTAB or a district court on the merits.
Should you run an FTO against US11129696B2 before launching orthodontic planning software?
Any company developing or commercialising computer-aided orthodontic treatment planning software — including clear-aligner design tools, AI-driven bracket placement systems, or digital simulation platforms — should conduct a freedom-to-operate assessment against US11129696B2. The patent remains fully enforceable, and the without-prejudice dismissal in this case provides no safe harbour for third parties. This is particularly relevant for teams whose products seek or hold Special 510(K) clearance using BRIUS Planner or related software as a predicate device.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim-level overlap between US11129696B2 and your product’s technical feature set. Eureka can identify prosecution history file wrappers, claim amendment records, and related family members that may extend protection beyond the granted claims. For organisations operating in the dental AI and orthodontic planning software sector, Eureka’s landscape analysis tools can also surface co-pending applications and divisional filings that may represent future assertion risk.
Run a freedom-to-operate analysis on US11129696B2 to assess your product’s exposure
Run FTO in Eureka →Similar orthodontic software and dental AI patent cases in U.S. district courts
Explore patent litigation involving computer-aided orthodontic treatment planning software and dental AI systems filed in C.D. Cal. and related U.S. district courts.
What this case signals for the orthodontic software IP landscape
A mutual without-prejudice exit after 472 days leaves US11129696B2 in play — and raises watch-list questions for every competitor in digital orthodontics.
Without-prejudice exits preserve enforcement optionality for patent holders
Brius retains the full right to assert US11129696B2 against Swift Health, USC, or any third party. Companies in computer-aided orthodontic treatment planning should treat this dismissal not as a resolution but as a pause. Monitoring Brius’s licensing activity and any new filings against competitors is advisable for portfolio strategy purposes.
USC’s presence signals potential university-origin patent complexity
The involvement of the University of Southern California as a co-defendant — rather than a co-plaintiff — is an unusual posture that may reflect contested ownership, licensing disputes, or Bayh-Dole Act considerations around federally funded research. R&D teams building on academic orthodontic research should assess whether upstream university IP rights could affect freedom to operate in this technology area.
Brius v Swift — key questions answered
The patent at issue is US11129696B2 (application US16/292126), which covers technology underlying the BRIUS Planner Software, an FDA-cleared computer-aided orthodontic treatment planning tool. The case was filed as a declaratory judgment action in the Central District of California on 27 September 2022.
The case was dismissed pursuant to a stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), signed by all parties. A without-prejudice dismissal means no court ruled on the merits of any claim. The public record does not disclose whether a private settlement, licensing agreement, or covenant not to sue was reached between the parties alongside the procedural dismissal.
USC appears as a co-defendant alongside Swift Health Systems, an unusual posture that may suggest contested patent ownership, a disputed licensing arrangement, or issues arising under the Bayh-Dole Act if the underlying research was federally funded. The public record does not confirm the exact basis for USC’s involvement, but practitioners should consider university IP rights when assessing the ownership chain of this patent.
No. The dismissal was without prejudice and on a purely procedural basis — no court adjudicated the validity, enforceability, or infringement of US11129696B2. The patent remains presumptively valid and fully enforceable. Third parties in the orthodontic planning software space should not treat this dismissal as a clearance of the patent.
The Special 510(K) pathway indicates the FDA reviewed BRIUS Planner Software against a predicate device and found substantial equivalence. In patent terms, this regulatory designation matters because competitors seeking 510(K) clearance using BRIUS Planner as a predicate device may face both regulatory and patent risks if their product’s features overlap with US11129696B2’s claims. The intersection of FDA clearance strategy and patent enforcement is a growing concern in dental AI software.
PatSnap Eureka searches patents and litigation data to answer instantly.